- The company’s strong growth is likely to suffer as a result of the pandemic, but we think this is only a temporary blip.
- The company rapidly adjusted and developed two COVID-19 tests for which demand is now ramping rapidly, and demand for their other tests will resume growth near term.
- The cost of rolling out the new tests and decline in their core business impacted results negatively, but this will be temporary as well.
- The end result is likely to be better as the costs are consumed, the COVID-19 tests ramp, and their existing business resurges.
Fulgent’s COVID-19 Tests Are Ramping Fast, But Their Other Tests Are Suffering
June 24th, 2020 · No Comments